ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2546

Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer

Natalia V. Zamora1, Harish Siddhanamatha2, Andrea Barbo3, Jean Tayar4, Heather Lin5 and Maria Suarez-Almazor6, 1Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, 4Department of Gentic Internal Medicine-AT & EC, The University of Texas, MD Anderson Cancer Center, Houston, TX, 5Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, 6Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologic agents, cancer and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic therapy for rheumatoid arthritis (RA) downregulates the immune response. Tumoral immunity is an important host mechanism against cancer progression, and for this reason, biologic therapy is often discontinued when a patient with RA develops cancer. Objectives: To determine the utilization of biologic therapy in patients with RA and cancer, after their cancer diagnosis.

Methods: We performed a retrospective cohort study of patients with RA and cancer seen at National Cancer Institute designated Comprehensive Cancer Center between 2002 and 2014. Patients were initially identified as having RA if they had a claim with a diagnostic code for RA (714) according to the International Classification of Diseases (ICD-9). Two independent reviewers examined all electronic medical records, and selected patients that fulfilled the following criteria in addition to a claim code: age ≥ 18 years, diagnosis of RA by a rheumatologist, and/or current or prior use of a DMARD or biologic agent. Patients with more than one primary or non-melanoma skin cancer were excluded. Descriptive statistics were generated to summarize patient characteristics, biologic use, and time to biologic therapy onset after cancer diagnosis. Kaplan-Meier methods were used to estimate time from biologic therapy onset to recurrence.

Results: 1719 patients met the inclusion criteria. Of these, 563 had received biologic therapy at any time, before and/or after cancer diagnosis. Most were female (72%), with a mean age at cancer diagnosis of 59 years (±13 years). Eighty-one had a follow-up of less than 3 months after cancer diagnosis and were not included in the analysis; 43 had discontinued biologic therapy before the cancer diagnosis; 313 were receiving biologic therapy at the time of cancer diagnosis, and in this group 225 (72%) discontinued therapy within 3 months of diagnosis, and 88 (28%) continued treatment. In addition, 126 patients initiated biologic therapy after their cancer diagnosis with a median of 8 years (range 0.04-39). Overall, 214/1719 (12%) of the patients with RA received a biologic after their cancer diagnosis. The most common tumor site among the 214 patients was breast (28%) followed by lymphoma and prostate in 7% each, and melanoma in 6%. Biologic therapies included: tumor necrosis factor inhibitors (TNFi) (88%), rituximab (7%), abatacept (4%), and tocilizumab (1%). Almost 20% switched biologic therapy at a later stage. Fifty-seven (27%) patients who received biologic therapy had active cancer or developed a recurrence during follow-up, and 14 (7%) died. Recurrence/active cancer rate was 12% in first year after starting biologic therapy (or after diagnosis of cancer if biologic had been continued), 16% by 2 years, and 33% by 5 years.

Conclusion: Biologic therapy was used in 12% of patients with RA after their cancer diagnosis, most frequently TNFi. One third had active cancer or a recurrence during follow-up. Additional controlled studies are needed to determine if the risk of cancer recurrence is higher in patients with RA receiving biologic therapy after developing cancer.


Disclosure: N. V. Zamora, None; H. Siddhanamatha, None; A. Barbo, None; J. Tayar, None; H. Lin, None; M. Suarez-Almazor, National Institute for Musculoskeletal and Skin Disorders, 2.

To cite this abstract in AMA style:

Zamora NV, Siddhanamatha H, Barbo A, Tayar J, Lin H, Suarez-Almazor M. Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/utilization-of-biologic-therapy-in-patients-with-rheumatoid-arthritis-and-cancer/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utilization-of-biologic-therapy-in-patients-with-rheumatoid-arthritis-and-cancer/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology